

Issues Concerning Extraction Efficiency, Methods, and Direct dPCR

by Ross Haynes

National Institute of Standards and Technology

April 10, 2013

Sample Prep & Target Enrichment

Boston, MA

Disclaimer


- Views expressed in this presentation are the author's opinion and do not represent the opinion of NIST or the Department of Commerce.
- Any mention of commercial products within this presentation is for information only; it does not imply recommendation or endorsement by NIST, nor does it imply that the products are the best available.

Agenda

- Extraction
 - Efficiency (relative vs. absolute)
 - Overview of traditional methods
- Alternates to traditional extractions
 - Liquid based
 - Direct PCR methods
- Direct digital PCR
 - NIST experiences
 - Considerations


Extraction Efficiency

- Relative: compared to another technique
 - New technique > Organic extraction



Extraction Efficiency

- Absolute: compared to amount of input material
- Mummy et al found ~ 15 % efficiency using 3 commercial kits (range 0 % to 45 %)
 - Lambda DNA in plasmid



DNA Extractions

- Steps:


- Lysis
- Separation
- Purification/wash
- Recovery

- Benefits

- Clean DNA

- Limitations

- No method is 100 % efficient



DNA Extractions

- Steps:

- Lysis 90 % efficient
- Separation 90 % efficient
- Purification/wash 90 % efficient
- Recovery 90 % efficient

Overall 66 % efficient



Efficiency probably not uniform
But we have to consider that lysis may not be 100 % efficient.

- Benefits

- Clean DNA

- Limitations

- No method is 100 % efficient

Alternate Methods

- Liquid based methods

- E.g. DNazol Direct


- Add reagent to sample
- Incubate
- Add directly to PCR

- Benefits

- All DNA contained in one tube


- Limitations

- Reagents may not lyse all cell or virus particles
- Reagents may contain PCR inhibitors
 - 1/10 dilution required



Extraction Efficiency

- People
 - Training
 - Education
 - Motivation
 - Sleep
- Robots
 - Set-up
 - Maintenance



Direct PCR

- Sample added directly to PCR mix
- Hot start used as lysis method
- Polymerases resistant to inhibition

- Thermo Scientific – Phusion polymerase
 - “Tolerant of many PCR inhibitors”
 - End point PCR protocols
 - Research Use Only
 - No 5' to 3' nuclease activity (not suitable for TaqMan probes)

1) Create a PCR mastermix as if for qPCR as if for qPCR

2) Aliquot across 100s or 1000s of wells




3) Thermal cycle as if for qPCR & count wells with detectible amplification at any cycle

4) Use Poisson statistics to determine concentration of starting material

dPCR



?
pg/uL



Direct dPCR


1) Create a PCR mastermix as if for qPCR

Virus particles instead of template DNA




?
pg/uL

2) Aliquot across 100s or 1000s of wells




3) Thermal cycle as if for qPCR & count wells with detectible amplification at any cycle

Hot start to lyse virus particles




Exhaustive cycling to ensure lysis & amplification of all target molecules

4) Use Poisson statistics to determine concentration of starting material




1st experiment direct dPCR

- NIST standard protocol Fluidigm 12.765
 - 10 minute hot start and 60 cycles
- Many late amplifications – inefficient lysis



0.03 % of amplifications
were in the last 10 cycles
1 out of 3763




3.6 % of amplifications
were in the last 10 cycles
126 out of 3476

1st experiment direct dPCR


- Are we detecting all virus particles?
 - No, late amplifications indicate the hot start is inefficient at lysing viruses
- Solution add more cycles & lysing steps
 - 10 min hot start
 - Every 5 cycles 2 min at 95 °C (first 25 cycles)
 - 85 cycles total

2nd series direct dPCR

- Extra incubations at 95 °C
- 85 cycles total



0.04 % of amplifications
were in the last 10 cycles
1 out of 2443



0.75 % of amplifications
were in the last 10 cycles
28 out of 3739



2nd series direct dPCR

- Still some evidence that all virus particles have not been lysed
 - Additional cycles may not be enough
- Solution: run excessive number of cycles
 - 100 cycles with extra “hot starts”
- Question: will enzyme (Taq Gold – ABI Gene Expression MM) be active at 100 cycles?


Stress Test Polymerase

- Master mix (sans DNA) cycled on standard thermal cycler
- Template DNA added
- Run qPCR on 7500


Conclusion: cycling has little to no effect on polymerase activity
Plateau likely due to consuming dNTPs



100 cycle direct dPCR




0.04 % of amplifications
were in the last 10 cycles
1 out of 2446



0.20 % of amplifications
were in the last 10 cycles
7 out of 3501

Concentration

- Do additional cycles change result?



Considerations

- Adding cycles adds time & reduces throughput
- Exhaustive cycles gives confidence that all DNA molecules present were amplified
- Principle of diminishing returns
 - Rare very late amplifications may not be significant
- End point systems: Are additional cycles significantly changing the measured concentration?

Considerations (cont.)

- What are you trying to do?
 - Quantifying standard – correct answer
 - Patient sample – would change/variation affect medical decisions?
 - Is ± 0.5 log close enough? $\pm 5\%$? $\pm 1\%$?
- Dead volume – portion of the sample is not analyzed

	Fluidigm 12.765	Bio-Rad QX100	Life Technologies Quant Studio 3D
Input volume	8 μL	20 μL	variable
Volume analyzed	4.59 μL	10 to 18 μL	up to 20 μL
% Analyzed	57%	50 to 90 %	up to 100 %

Future Directions

- Correlate particle (or cell) count with direct dPCR measurement
- Estimate of absolute extraction efficiency comparing direct dPCR with extraction followed by dPCR.

Conclusions

- Direct dPCR may be acceptable with heat lysis
- Modifications may be necessary
 - Additional cycles
 - Additional heating (lysing) steps
 - Polymerases resistant to inhibition with 5' to 3' nuclease activity
- Purpose and required accuracy may affect optimization scheme

Questions

Ross Haynes

Ross.Haynes@nist.gov

This presentation will be available online at

http://www.nist.gov/mml/bmd/genetics/clinical_dna.cfm

Or Google “CDIR NIST”